The US Food and Drug Administration last week gave its approval for new indications for currently marketed drugs – Votrient (pazopanib from the UK-based GlaxoSmithKline (LSE: GSK) and Afinitor (everolimus), from Switzerland’s Novartis (NOVN: VX).
Specifically, the FDA cleared Votrient to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Analysts forecast modest sales for the GSK product, with global sales expectations peaking around $500 million in 2016, according to forecasts from Thomson Reuters Pharma. Votrient generated global sales of about £100 million ($161 million) last year and achieved an 18% total prescription share in the US advanced renal cell carcinoma market by end 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze